Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SITC 2021 | BASECAMP-1: a study to identify patients that may benefit from future CAR T-cell therapy

Julian Molina, MD, PhD, Mayo Clinic, Rochester, MN, gives an update on the BASECAMP-1 trial (NCT04981119), an observational study to identify relapsed solid tumor patients with human leukocyte antigen (HLA) loss of heterozygosity (LOH) and leukapheresis for future CAR T-cell therapy. Although, CAR T-cells have showed clinical outcomes in hematologic malignancies, its use in solid tumors has been proven difficult due to a lack of tumor-specific targets that discriminate cancer cells from normal cells. Patients participating in the BASECAMP-1 study will be screened to identify germline HLA-A*02 heterozygosity by central next-generation sequencing (NGS). If HLA-A*02 heterozygosity is confirmed, primary archival tumor tissue will be analyzed to determine if somatic tumor HLA-A*02 LOH is present. If the tumor demonstrates HLA-A*02 LOH and the patient screens eligible, the patient will undergo leukapheresis. In the future, if relapses occurs, banked T-cells are available for CAR T-cell therapy. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.